Century Therapeutics, Inc.
IPSC
Rank in Stocks
#14965
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering... Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogeneic, induced pluripotent stem cell (iPSC)-derived CAR-iNK cell therapy. This therapy is specifically designed to target CD19 in patients with B-cell lymphoma that has relapsed or proven refractory to previous treatments. In addition to its lead candidate, the company's robust pipeline features several other therapeutic assets: CNTY-103: A CAR-iNK candidate aimed at CD133 + EGFR for recurrent glioblastoma. CNTY-102: A CAR-iT therapy targeting CD19 + CD79b, intended for relapsed or refractory B-cell lymphoma and other B-cell cancers. CNTY-104: A multi-specific CAR-iT or CAR-iNK candidate in development for acute myeloid leukemia. CNTY-106: Another multi-specific CAR-iNK or CAR-iT candidate for multiple myeloma. Established in 2018, Century Therapeutics, Inc. is based in Philadelphia, Pennsylvania.
Share Price
$1.38
Last synced: 2026-11-18
Market Cap
$284.89M
Change (1 day)
0.73%
Change (1 year)
181.23%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Century Therapeutics, Inc. (IPSC)
Category
Healthcare
P/S ratio for Century Therapeutics, Inc. (IPSC)
P/S ratio as of November 2026 TTM: 0.00
According to Century Therapeutics, Inc.'s latest financial reports and stock price, its current price-to-sales ratio (TTM) is 0.00. At the end of 2025 the company had a P/S ratio of 0.79.
P/S ratio history for Century Therapeutics, Inc. from 2019 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2025 | 0.79 | -93.46% |
| 2024 | 12.06 | -86.32% |
| 2023 | 88.11 | 54.61% |
| 2022 | 56.99 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| 18.29 | - |
US
|
|
| 10.51 | - |
US
|
|
| 35.79 | - |
US
|
|
| 4.19 | - |
AU
|
|
| 6.63 | - |
BE
|
Questions about Century Therapeutics, Inc.'s P/S ratio
What was Century Therapeutics, Inc.'s P/S ratio in 2025?
In 2025, Century Therapeutics, Inc.'s P/S ratio was 0.79, compared with 12.06 in 2024.
How has Century Therapeutics, Inc.'s P/S ratio changed since 2020?
From 2020 to 2025, Century Therapeutics, Inc.'s P/S ratio was highest in 2023 (88.11) and lowest in 2021 (0.00).
How does Century Therapeutics, Inc.'s P/S ratio compare with similar companies?
Century Therapeutics, Inc.'s P/S ratio (0.00) is lower than that of all 5 similar companies listed above. The highest among them is Moderna, Inc., with 35.79.